-logo-1200x675.png?v=20241011142232){kind=logo}
Getinge (OTCMKTS:GNGBY – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday. The company traded as high as $27.0525 and last traded at $26.8510, with a volume of 357 shares traded. The stock had previously closed at $26.82.
Analysts Set New Price Targets
A number of research firms recently commented on GNGBY. UBS Group began coverage on shares of Getinge in a report on Wednesday, September 2nd. They set a “hold” rating for the company. Pareto Securities downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 24th. Nordea Equity Research lowered shares of Getinge from a “buy” rating to a “hold” rating in a report on Monday, August 31st. Finally, Zacks Research cut Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 17th. Four research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock currently has an average rating of “Hold”.
View Our Latest Analysis on GNGBY
Getinge Price Performance
The business’s 50 day moving average price is $25.31 and its two-hundred day moving average price is $22.58. The stock has a market cap of $7.44 billion, a P/E ratio of 24.85 and a beta of 0.95. The company has a current ratio of 1.31, a quick ratio of 0.74 and a debt-to-equity ratio of 0.26.
Getinge (OTCMKTS:GNGBY – Get Free Report) last posted its earnings results on Wednesday, October 21st. The company reported $0.32 earnings per share for the quarter. The firm had revenue of $875.58 million for the quarter. Getinge had a return on equity of 11.55% and a net margin of 8.20%. As a group, sell-side analysts expect that Getinge will post 1.38 earnings per share for the current fiscal year.
Getinge Company Profile
Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.
The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.
Read More
- Five stocks we like better than Getinge
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.
